EICHOR
● Active Not Recruiting
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)
Condition: Transfusion-dependent Alpha-Thalassemia · Transfusion-dependent Beta-Thalassemia · Sponsor: Agios Pharmaceuticals, Inc.
About this study
The primary objective of this study was to compare the effect of mitapivat versus placebo on transfusion burden in participants with α- or β-transfusion-dependent thalassemia.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (75)
| Phoenix Children's Hospital | Phoenix, Arizona, United States | — |
| San Diego Hospital, UC San Diego Health | La Jolla, California, United States | — |
| Children's Hospital Oakland | Oakland, California, United States | — |
| Stanford Medicine | Palo Alto, California, United States | — |
| Boston Children's Hospital | Boston, Massachusetts, United States | — |
| Children's Hospital of Michigan | Detroit, Michigan, United States | — |
| Weill Cornell Medical Center | New York, New York, United States | — |
| Duke University Medical Center | Durham, North Carolina, United States | — |
| Penn Medicine - University of Pennsylvania Health System | Philadelphia, Pennsylvania, United States | — |
| Seattle Cancer Care Alliance, University of Washington | Seattle, Washington, United States | — |
| Hospital Das Clínicas da Faculdade de Medicina de Ribeirão Preto - USP | Ribeirão Preto, Brazil | — |
| GSH Banco de Sangue de São Paulo | São Paulo, Brazil | — |
+ 63 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.